Jiangsu Bioperfectus Technologies Co., Ltd.

(SSE:688399)

BioPerfectus, a public listed company on Shanghai Stock Exchange (SSE:688399), has been one of the leading molecular diagnostic solution providers specialized in infectious diseases ever since 2010. With headquarters located in Jiangsu, subsidiaries in Shanghai, Beijing, Xi’an, Taizhou, Hainan, and Yinchuan. Bioperfectus is pioneering in molecular diagnostics market with our products ranging from real time PCR kits, nucleic acid extraction systems, rapid tests and automation laboratory devices. Young and passionate, Bioperfectus people are working steadily and firmly to achieve our dream of creating a healthier future for our next generations.

62,000+㎡

An industrial park of over 62,000㎡ integrating fully self-innovative R&D, production, warehousing, logistics, sales, marketing and customer service divisions catering for various business scenarios

800+

Over 800 Bioperfectus people’s permission gathering the perseverance and determination to fight against the global pandemic

5,000,000+

Production capacity ramping up to more than 5 million tests/day ensuring the quick sufficient response to infectious diseases

global presence

90 Countries within a year

Bioperfectus Products & Service have been distributed to over 80+ countries around the globe within only one year since the international business established.

10000 Machinery spots

Bioperfectus Nucleic Acid Extraction Solutions
were launched in over 10,000 laboratories
globally with a well-trained and quick-response
customer service team.

Product Center

News Center

07-012022

Declaration on the Effectiveness of Test Kits against BA.4 and BA.5

07-012022

WHO Director-General Tedros Adhanom Ghebreyesus Ph.D. said on 29 June 2022, COVID-19 cases are rising in 110 countries, driven by BA.4 and BA.5 in many places, causing overall global cases to increase by 20%, and deaths have risen in three of the six WHO regions. The SARS-CoV-2 variants BA.4 and BA.5 were first detected in South Africa in January and February 2022 and became dominant locally in May 2022. As of 12 May 2022, ECDC reclassified Omicron sub-lineages BA.4 and BA.5 from variants o...

06-282022

Bioperfectus Monkeypox Virus PCR Kit to Support Testing Across Africa

06-282022

June 28, 2022, Shanghai, China Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as Bioperfectus) Deputy General Manager Mr. TUNC MERT SAYIN addressed the opening ceremony of the Training Workshop on Monkeypox Diagnosis Using Real Time PCR Technique held by Africa Centers for Disease Control and Prevention (*hereinafter refer to as Africa CDC), African Union in collaboration with Nigeria Centre for Disease Control (Nigeria CDC) and African Society for Laboratory Medicine (AS...

06-222022

Next pandemic? Concerns growing as monkeypox virus cases surge

06-222022

The monkeypox virus, shown here in a colored electron micrograph, typically spreads by skin-to-skin contact or respiratory droplets. Sexual transmission may play a role in the new outbreak. CDC/CYNTHIA S. GOLDSMITH/SCIENCE SOURCE On 17 June, the WHO released its latest update on the Monkeypox outbreak situation. The sharp growth of confirmed cases during the last two months indicates increasing uncertainty of the endemic progress. Between 1 January and 15 June 2022, a cumulative total of 21...

Learn More

Service Network

Support is only one step away

A good after-sales service is essential for efficiency of workload in PCR laboratory. Bioperfectus delivers most perfect service via our authorized distributors and global service center. With well-experienced service staff, sufficient spare-part inventory and fast global logistics, Bioperfectus aims to provide with the satisfactory solutions to our end users.We offer 24/7 after-sales service, prompt response and periodical training programs.

CONTACT US NOW